Bayer christens $250M cell therapy 'launch facility' in Berkeley
Fierce Pharma
OCTOBER 10, 2023
Now, as BlueRock Therapeutics advances its lead prospect, its parent company Bayer is ready to kick production into high gear. . | Despite the promise of cell therapies, manufacturing the personalized medicines at scale has been a limiting factor for many companies.
Let's personalize your content